Phase 4 Migraine Trial, Recruiting NCT06509503 Sponsor: Kafrelsheikh University Condition: Migraine
Back to Migraine

Phase 4 Migraine Trial, Recruiting

NCT06509503
Recruiting Phase 4

Who may be able to join

AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI

Who might be able to join this trial:

  • Women aged 18 to 55 years who have been diagnosed with migraines, based on a specific set of international headache guidelines
  • Women who are using either a combined oral contraceptive pill or a non-hormonal (mechanical) form of contraception

Who may not be able to join:

  • People who have a major neurological condition, such as epilepsy, stroke (any type), multiple sclerosis, mitochondrial diseases, or brain tumours
  • People who are currently pregnant, breastfeeding, or have gone through menopause
  • People who have a medical reason why they cannot take ibuprofen or propranolol (confirm with trial site)

Important: Always verify eligibility with the trial site directly before applying.

Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.

This is a simplified plain English summary of the eligibility criteria. Full criteria are set by the trial investigators and may include additional requirements not shown here. Never self-exclude from a trial based on this summary. Contact the trial site directly to confirm your eligibility.
Last synced 15 July 2026
Phase 4 trials study a drug that has already been approved, monitoring long-term safety and effectiveness in real-world use.

Contact this trial

Phone: 2001009606828

Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.

GP referral letter

Print a one-page summary to share with your doctor.

Trial details

Status
Recruiting
Phase
Phase 4
Sponsor
Kafrelsheikh University
Registry
ClinicalTrials.gov
Start date
15 July 2024
Est. completion
15 May 2025

Where this trial is recruiting

🇪🇬 Egypt

Primary endpoints

The percentage of patients who achieved ≥ 50% change in the monthly migraine days frequency compared to the baseline frequency

Can't join this trial?

Expanded access pathways

If this trial is not available to you, other access pathways may exist. In Australia, the TGA Special Access Scheme allows access to unapproved therapeutic goods for individual patients.

TGA Special Access Scheme information

Find other recruiting trials on ClinicalTrials.gov

Data last synced from ClinicalTrials.gov: 15 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.

Trial recruitment status can change without notice between our nightly data updates. Always contact the trial site directly to confirm current recruitment status before making any decisions or travel arrangements.

View original record on ClinicalTrials.gov